Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Completed Initiated Jan 18, 2024 (3 years ago)

Mesalamine Delayed-Release Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Cause type: Microbial contamination

Bacteria, mold, yeast or other microorganisms detected in the product. Contamination can occur from water systems, equipment or handling, and can cause infection. All microbial contamination recalls.

What was recalled

Mesalamine Delayed-Release Tablets, USP 1.2 g per tablet, Rx Only, 120 Tablets per bottle, Once Daily, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Limited Survey No. 259/15, Dadra-396 191 (U.T. of D & NH), INDIA, NDC 63304-175-13.

Affected NDC 63304-0175-13

Compare with the code on your package — it is the most precise check available.

Drug: Mesalamine

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Mesalamine
NDC 63304-0175
1.2 g/1 Tablet, Delayed Release
Oral
Sun Pharmaceutical Industries, Inc. Rx
Recalling firm
Sun Pharmaceutical Industries INC
NDC code
63304-175-13
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0268-2024 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now completed, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Mesalamine recalls

See all
Class II · Moderate risk

Mesalamine Delayed-Release Tablets

Failed Dissolution Specifications: Out-of-specification dissolution results were obtained during stability testing.

Terminated Dissolution failure Teva Pharmaceuticals USA NDC 0591-2245-22 D-0069-2021
Class II · Moderate risk

Mesalamine Delayed-Release Tablets

Failed Dissolution Specifications: Low out of specification dissolution result observed during stability testing.

Terminated Dissolution failure Teva Pharmaceuticals USA NDC 0591-2245-22 D-0862-2020
Class III · Low risk

Pentasa (mesalamine)

Presence of Foreign Tablets/Capsules; 500 mg capsules were found in bottles labeled to contain 250 mg capsules

Terminated Particulate / foreign matter Shire PLC NDC 54092-189-81 D-0432-2017

Other recalls by Sun Pharmaceutical Industries INC

All 2024 recalls
Class II · Moderate risk

Carbamazepine Tablets

CGMP Deviations; black spots found on tablets from burnt excipient during manufacturing

Ongoing cGMP deviation Sun Pharmaceutical Industries INC NDC 51672-4005-3 D-0770-2026
Class II · Moderate risk

Perampanel CIII Tablets

Labeling: Label Mix-up: 10mg Perampanel CIII tablet was found in a Perampanel CIII bottle labeled Perampanel 6 mg tablets.

Ongoing Labeling / mix-up Sun Pharmaceutical Industries INC NDC 51672-4206-6 D-0628-2026